Why are investors excited about hair loss drugs? Will artificial intelligence make clinical trials run more smoothly? And how does a nonprofit pharma company compete in the M&A arena? We get into all that and more on this week’s episode of “The Readout LOUD,” STAT’s weekly biotech podcast. Veradermics CEO Reid Waldman joined us to discuss his company’s data, and why hair loss is such a trendy topic in biotech. Then, Servier Pharmaceuticals CEO David Lee joined us to discuss the company’s acquisition of Day One Biopharmaceuticals.
AI Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from The Readout Loud
398: A CAR-T biotech's dramatic turnaround, and drugmakers' tactics to drive more scripts
397: A pancreatic cancer breakthrough, and new hope for an off-the-shelf CAR-T treatment
396: A new trick for old science, and biotech VCs' scrambled playbook
395: Biotech investors' plea to Trump, and a busy M&A week
Get summaries like this every morning.
Free AI-powered recaps of The Readout Loud and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.